Other Clinical Trial - Validation of the REPS Prediction Tool

Status Completed

Clinical Trial Summary

Neuromuscular blocking agents' (NMBA) use during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Residual neuromuscular block (rNMB) after surgery is difficult to identify. We have recently developed the REsidual neuromuscular block Prediction Score (REPS), that predicts the risk for postoperative rNMB. Our primary objective is now to assess the predictive ability of the REPS for respiratory complications within seven days following general anaesthesia. The secondary objective is to compare the predictive values of REPS and train-of-four (TOF)-ratio below 0.90 for respiratory complications.

Clinical Trial Description

Residual neuromuscular blockade occurs in about 20-60% of patients and depends on compound and dose of NMBA reversal agent used. While on the one hand, NMBAs optimize surgical conditions and facilitate mechanical ventilation in patients with ventilator asynchrony, on the other hand, these agents have been associated with respiratory complications and increased risk of readmission after ambulatory surgery. A consensus in regard to guidelines and thresholds to define the optimal strategy to optimize surgical conditions is yet to be achieved. We have shown that utilization of non-depolarizing muscle relaxants and their reversal agents can be improved by dedicated quality improvement techniques. We have also recently developed the REPS, a tool that predicts postoperative rNMB. This is a retrospective, observational, cohort study based on on-file hospital data from Beth Israel Deaconess Medical Center, Boston, Massachusetts. The primary aim is to validate the dichotomized REPS (high-risk versus low-risk for rNMB which corresponds to a REPS >4 and <4, respectively) for the outcome of postoperative respiratory complications with BIDMC data. The investigators will utilize the pre-defined variables identified to predict residual neuromuscular blockade (REPS) at BIDMC. The secondary aim is to compare the predictive values of the dichotomized REPS with dichotomized train-of-four (TOF)-ratio (low TOF-ratio versus high TOF ratio which corresponds to a TOF-ratio <0.9 and >=0.9, respectively) for respiratory complications. ;

Study Design

Related Conditions & MeSH terms

Curarization, Postoperative Residual
Delayed Emergence from Anesthesia
Postoperative Respiratory Complication
Residual Neuromuscular Blockade

Clinical Trial Details

NCT number	NCT03585400
Study type	Observational
Source	Beth Israel Deaconess Medical Center
Contact
Status	Completed
Phase
Start date	June 29, 2018
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04619225` - Cardiac Output and Recovery Time	N/A
Recruiting	`NCT05992090` - Neuromuscular Blockade Monitoring Using Kine-myography vs Electromyography.
Completed	`NCT02146859` - Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia
Terminated	`NCT01678625` - Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade
Completed	`NCT03417804` - Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
Completed	`NCT03111082` - Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter?
Completed	`NCT04244266` - Observational Study in Bariatric Surgery
Completed	`NCT02939911` - Residual Neuromuscular Blockade in Pediatric Anesthesia
Completed	`NCT02660398` - Incidence and Severity of Residual Neuromuscular Blockade	Phase 4
Completed	`NCT03920670` - Comparison of the ToFscan and TetraGraph During Recovery of Neuromuscular Function in the Post Anesthesia Care Unit	N/A
Completed	`NCT01837498` - Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
Completed	`NCT02213848` - Effect of Calcium Chloride on Recovery From Neuromuscular Blockade	N/A
Completed	`NCT04352140` - Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting	N/A
Completed	`NCT04352127` - Visual and Electromyography Assessments in Response to Train-of-Four Stimulation of the Ulnar Nerve	N/A
Completed	`NCT04312256` - Thumb vs Great Toe Recovery	N/A
Withdrawn	`NCT03574337` - Residual Neuromuscular Blockade in Cardiac Surgery Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.